DOI: 10.1002/edm2.70316 ISSN: 2398-9238

Dipeptidyl Peptidase‐4 Inhibitors Associated Heart Failure Events in Adult Patients With Type‐2 Diabetes Mellitus Treated With Dipeptidyl Peptidase‐4 Inhibitors: A Systematic Review and Meta‐Analysis

Shishir Nepal, Shiva Prasad Nepal
Show PDF Cite

ABSTRACT

Introduction

DPP‐4 inhibitors use has been reported to cause heart failure events in patients with type‐2 diabetes. The FDA had also issued warnings concerning increased risk of heart failure events for alogliptin, saxagliptin and their combination with metformin.

Methods

Randomized controlled trials (RCTs) involving adult patients with type‐2 diabetes patients with or without history of cardio‐vascular disorders were included in the review. Cohort studies, case–control studies and other non‐RCTs, and studies involving paediatric patients were excluded. Data bases searched were PubMed/Medline, DOAJ, MDPI, Google Scholar and clinicaltrails.gov . The search was conducted in late January of 2026. Risk of bias was assessed using RoB‐2 tool for RCTs. Individual study outcomes were tabulated and summary measure was synthesized by meta‐analysis under random effect model; GRADE certainty of evidence was used; sub‐group analysis based on individual DPP‐4 inhibitors, follow‐up duration and placebo or other controls was done; systematic review was done under PRISMA 2020 Guidelines.

Results

The meta‐analysis was done under random effect computation model for all 29 included studies. The analysis for total of pooled 67,873 patients showed statistically insignificant association between the use of DPP‐4 inhibitors and heart failure with Risk Ratio (RR) = 1.06, 95% Confidence Interval (CI) 0.94–1.12. Sub‐group analysis found significant association of saxagliptin use with increased heart failure risk.

Conclusion

Results should be interpreted with caution because of several limitations of the study.

Trial Registration

PROSPERO, CRD420261288081

More from our Archive